Last reviewed · How we verify
Ruxolitinib 1.5% Cream
At a glance
| Generic name | Ruxolitinib 1.5% Cream |
|---|---|
| Also known as | Opzelura, INCB018424 phosphate cream |
| Sponsor | Icahn School of Medicine at Mount Sinai |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa (PHASE1)
- A Study to Assess the Safety and Efficacy of Ruxolitinib Cream in Participants With Genital Vitiligo (PHASE2)
- Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2) (PHASE3)
- Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1) (PHASE3)
- Study of the Safety and Efficacy of Ruxolitinib Cream for Non-Sclerotic Chronic Cutaneous Graft-Versus-Host Disease (PHASE2)
- A Real-world Study on the Influencing Factors of Efficacy of Ruxolitinib Cream in Vitiligo
- The Purpose of This Study is to Evaluate the Effects of Ruxolitinib Cream on Adults With Atopic Dermatitis Experiencing Sleep Disturbance. (PHASE4)
- A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ruxolitinib 1.5% Cream CI brief — competitive landscape report
- Ruxolitinib 1.5% Cream updates RSS · CI watch RSS
- Icahn School of Medicine at Mount Sinai portfolio CI